# Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC

> **NCT03041311** · PHASE2 · COMPLETED · sponsor: **G1 Therapeutics, Inc.** · enrollment: 107 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Trilaciclib
- **DRUG:** Placebo
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03041311
- **Lead sponsor:** G1 Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-29
- **Primary completion:** 2018-08-17
- **Final completion:** 2020-10-29
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2025-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03041311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03041311, "Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT03041311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*